Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
NCT07119125Phase 1Active, not recruiting
- Sponsor
- Monte Rosa Therapeutics
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRT-8102 in 19p13.3 microduplication syndrome (6 arms), sponsored by Monte Rosa Therapeutics. Primary endpoint: Safety and tolerability of single and multiple doses at 56 days. Started Jun 2025; status: active, not recruiting.
02
Drugs
MRT-8102
03
Conditions
19p13.3 microduplication syndrome
Beyond the preview
Go deeper on NCT07119125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119125.